



AMGEN

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Our belief—and the core of our strategy—is that innovative, highly differentiated medicines that provide large clinical benefits in addressing serious diseases are medicines that will not only help patients, but also will help reduce the social and economic burden of disease in society today.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies. We have a presence in more than 100 countries and regions worldwide and our innovative medicines have reached millions of people in the fight against serious illnesses. We focus on six therapeutic areas: cardiovascular disease, oncology, bone health, neuroscience, nephrology and inflammation. Our medicines typically address diseases for which there are limited treatment options.

AMGEN IN CHINA

Amgen entered in China since 2012 with the mission to serve patients by using science and biotechnology to improve health for Chinese patients and societies. Amgen China is present in approximately 100 cities across the country, with the national headquarters located in Shanghai. Amgen is committed to bringing innovative therapies for Chinese patients experiencing significant unmet needs, particularly around chronic conditions such as cardiovascular disease, bone health, inflammation, nephrology and so forth.

Driven by the commitment to act in the public interest and improve drug accessibility, we strive to provide more treatment options for patients. We fully leverage our long-standing development and biologics manufacturing expertise to develop biosimilars by exploring cooperation with leading domestic pharmaceutical companies to accelerate the development and launch of high quality biosimilars in China. In addition, we entered into strategic collaboration with a leading bio-tech company to expand our oncology presence in China and to jointly advance Amgen's oncology pipeline in China and globally. To improve patients' access to medicine, Amgen supported the China Charity Foundation (CCF) to initiate the Repatha Patient Assistance Program, providing patients suffering from homozygous familial hypercholesterolemia (HoFH) with free access to Repatha® (evolocumab) injections.

OUR MISSION

To Serve Patients

OUR VALUES

- Be Science-Based
- Compete Intensely and Win
- Create Value for Patients, Staff, and Stockholders
- Be Ethical
- Trust and Respect Each Other
- Ensure Quality
- Work in Teams
- Collaborate, Communicate and Be Accountable

AMGEN QUICK FACTS

Global Headquarters – Thousand Oaks, CA

Stock listing (NASDAQ): AMGN

Staff: Approximately 24,000 worldwide

2020 Financial Highlights:

- Total Revenue: \$25.4 billion
- Product Sales: \$24.2 billion
- Non-GAAP R&D expense: \$4.1 billion

China Headquarters – Shanghai

18/F, Platinum Tower

No. 233 Taicang Road

Huangpu District, Shanghai 200020

Representative Office – Beijing

7/F Fortune Financial Center

No. 5 East 3rd Ring Road

Chaoyang District, Beijing 100020

Innovative Medicines in China

- Repatha® (evolocumab)
- Prolia® (denosumab)
- Otezla® (apremilast tablets)

Recognitions

- 2019 China Best Employer
- CEO Cancer Gold Standard™
- 2019 Top10 Pioneering Medical Enterprises
- 2020 Anti-Pandemic Hero Company
- 2020 Aon Healthiest Employer
- Award-Excellent Anti-pandemic Award
- 2020 Corporate Social Responsibility Award
- 2020 Top10 Pioneering Medical Enterprises

AMGEN® 安进

Last updated on September 2021

AMG_Amgen Corporate_CN_2021_10_016

CHAMPIONING A PREDICT AND PREVENT APPROACH TO HEALTH

Through collaboration with multiple stakeholders, Amgen supports the building of a Predict and Prevent healthcare ecosystem based on local demands to improve the life quality of Chinese patients and help achieve the “Healthy China 2030” vision. Amgen supported the China National Health Development Research Center of the National Health Commission to launch the program of “Building of High-Quality and Efficient Health Service System and Empirical Study in the Context of Aging”.

To improve the awareness and prevention of pan-vascular disease, Amgen partnered with the China Cardiovascular Association (CCA) to develop the China Pan-Vascular Disease Prevention & Control Blue Paper, published in June 2019. In July, Amgen supported CCA to open the Chinese ASCVD Prevention and Control Centre, to help reduce the risk of cardiovascular events in patients through preventative measures.

To draw attention to the bone health of women, Amgen joined hands with the China Women's Development Foundation (CWDF) to launch “Joyful Bone-Women Osteoporosis Disease Education Campaign” in October 2020. In the same year, Amgen officially introduced Fight the Fracture public education campaign to China, providing educational information, tools and resources to help fight fragility fractures. In December, Amgen worked with partners at all levels and kicked off Power Bone Program to enable an integrated prevention and treatment system for Chinese patients with fragility fractures. In 2021, Amgen cooperated with industry partners to build a community-based osteoporosis management system to benefit more patients in need.

SUPPORTING THE NEXT GENERATION OF SCIENTISTS

The Amgen Foundation seeks to advance excellence in science education to inspire the next generation of innovators and invest in strengthening communities where Amgen staff members live and work. In September 2017, The Amgen Foundation brought the Amgen Biotech Experience (ABE) program to China, with more than 500 teachers and students from 23 high schools in Shanghai participating and gaining first-hand experience of biology labs at classrooms. In July 2019, Amgen Scholars Program opened admissions for the first time in China, partnering with Tsinghua University. The Tsinghua Amgen Scholars Program received over 282 applications from over 50 countries, from which 15 undergraduate students were accepted and offered premier summer research opportunities at world-leading educational and research institutions.

For more information, visit www.AmgenInspires.com.

For more information,
Please visit www.amgen.cn,
And follow us on Amgen China Corporate
WeChat account “安进 Amgen” & Amgen
China WeChat Channels:

